MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • MassDevice Today
    • Cardiovascular
    • Clinical Trials
    • Legal News
    • Orthopedics
    • Regulatory/Compliance
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • More MedTech
    • Cosmetic/Aesthetic
    • Diabetes
    • Dialysis
    • Distribution
    • Imaging
    • Otolaryngology Ear, Nose & Throat
    • Pharma
    • Respiratory
    • Wound Care
  • Blog
  • DeviceTalks Podcasts
  • Resources
    • About MassDevice
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • White Papers
  • DeviceTalks
Home » FDA panel decision means Abiomed will need new PMA for Impella pump

FDA panel decision means Abiomed will need new PMA for Impella pump

December 7, 2012 By Ingrid Mezo Leave a Comment

Share
Abiomed's Impella heart pump

An FDA panel decision will require some cardiovascular pump makers to submit their already-approved medical devices for review under the FDA’s more stringent premarket review pathway.

The federal watchdog agency’s Circulatory Devices Advisory panel this week acknowledged that non-roller-type cardiopulmonary bypass blood pumps are life-supporting, but recommended against shifting them to a lower-risk category for temporary ventricular support. Panelists also suggested down-classification into Class II (special controls) for cardiopulmonary and circulatory bypass therapy.

The decision sent ABMD shares spiraling downward today, dropping as low as $12 per share in morning trading before recovering completely to reach last night’s close of $12.88 by about 3:30 p.m.

The Danvers, Mass.-based cardiac devices maker said that it believes it’s well-positioned to undergo PMA review for its star line of Impella cardiovascular pumps and that the devices won’t have to come off of shelves while the company navigates the regulatory approval process.

The FDA defines non-roller-type cardiopulmonary bypass pumps (NRPs) as devices that use a method other than revolving rollers to pump the blood through the cardiopulmonary bypass circuit during bypass surgery. Although these devices are classified in the FDA’s Class III category, designating devices that pose the greatest risk to patients, they fall under a pre-1976 medtech amendment that has allowed the devices to pass through the less-stringent premarket notification 510(k) review process rather than the PMA pathway.

There are 2 types of NRPs: The 1st variety, centrifugal-type pumps, use a rotor to "to impart energy to the blood in an extracorporeal circuit through centrifugal forces," and usually contain an oxygenator, according to FDA. They are intended to provide cardiopulmonary support over a span of 6 or fewer hours during cardiopulmonary or circulatory bypass. This type of pump has been on the market for 36 years and has well-established, clinically meaningful benefits, the agency notes.

The 2nd type of NRP, catheter-based axial-type pumps, are temporarily placed within the heart or vasculature to provide ventricular support only, according to the FDA. They are not designed for use with an oxygenator, and are comprised of a pump motor, a cannula and a catheter that connects to a console. This type of pump has recently been introduced to the market and the federal watchdog agency considers it to be an evolving/new technology.

A majority of panelists on the Circulatory System Devices Panel, which convened in Gaithersburg, Md., concurred with FDA that NRPs should remain in the higher risk Class III for temporary ventricular support because of the short history of catheter-based axial-type pumps on the market, their resulting undefined risk profile and insufficient evidence of safety and effectiveness. A few panelists, however, recommended down-classifying NRPs to the lower-risk Class II for all indications.

Panelist Dr. Keith Allen of the Mid America Heart Institute in Kansas City, MO, explained why he and a majority of other panelists concurred with the FDA in recommending that NRPs remain in the higher risk Class III category for temporary ventricular support.

"As a user of these devices I can’t fathom how they can be regulated by special controls when they’re not the same devices, and to me that seems an impossibility," he said.

"To me when you have devices in a class as a whole that are very similar, are manufactured the same and do the same thing, then I think that’s an appropriate way to manage them with special controls," Allen continued. "But in this case, you’ve got different types of devices and they need to be managed differently and they need to be separated and be classified. And I think that if you did look at the data as a PMA and the Protect II trial came up to panel … a trial that was stopped prematurely and didn’t meet its primary endpoint and had a composite endpoint that had 10 pieces to it with a lot of post-hock analysis, I can’t imagine any panel approving that as a primary PMA panel.

"So, I think we need to lend credence to what the FDA is asking for, what this panel is charged with, which is: give clarity to the field of mechanical circulatory support," Allen underscored. "I don’t care how we got into this mess, but let’s not kick the can down the road, like they’re doing down the road, and let’s clean this mess up and classify devices that are the same, put those in one bucket, and devices that are different, put them in a bucket, which is all I think the FDA is asking."

The risks of NRPs intended for cardiopulmonary and circulatory bypass, according to FDA, include alteration in blood composition, inadequate tissue perfusion, embolism, problems related to duration of use, fluid leakage, adverse tissue reaction and infection. For the temporary ventricular support indication, the risks also include structural/tissue damage to the heart, local heat generation and problems with flow dynamics.

Abiomed, manufacturer of the Impella catheter-based axial-type pump says it will work to strengthen the body of clinical evidence to support the safety and effectiveness of its device. "We look forward to collaborating with the FDA on next steps and agree with the 515i Panel’s feedback that our existing data, combined with our U.S. registry, position us to work with the FDA to submit a PMA application," said Abiomed president, chairman & CEO Michael Minogue in prepared remarks.
"We welcome the opportunity for a PMA to strengthen our existing marketing clearances and expand the indications for Impella patients."

With more than 30 speakers, 25 panels and 4 tracks, you can't miss DeviceTalks Minnesota

textadimage On June 4-5, DeviceTalks Minnesota is taking over the Twin Cities medtech industry with one of the most anticipated conferences of the spring.

Join leaders from 3M, Abbott, Bigfoot Biomedical, Boston Scientific, Cardionomic, CMF Solutions, Cyient, Google Mayo Clinic, Medical Alley, Medtronic, NxThera, Opus College, Relievant Medsystems, University of Minnesota, Star Tribune, Smith & Nephew, Spry Health, Zimmer Biomet and many more when you register today.

Use the code "DTWeb" to save 15% on the cost of registration. 

REGISTER TODAY

Filed Under: Cardiac Assist Devices, Food & Drug Administration (FDA), News Well, Pre-Market Approval (PMA), Regulatory/Compliance Tagged With: Abiomed

In case you missed it

  • Brainlab releases VersaHD high-res planning algorithm
  • Varian wins FDA nod for Calypso anchored beacon transponder for SBRT therapy
  • Nephros releases preliminary Q1 earnings, raises $3m
  • Olympus inks endoscope image sharing deal with InterSystems
  • FDA approves IDE trial for Urotronic’s drug-coated balloon
  • FDA approves Angel Medical System’s AngelMed Guardian cardiac monitor
  • Curetis launches diagnostic cartridge for urinary tract infection
  • Hologic touts study comparing NovaSure to Minerva’s endometrial ablation device
  • How Minnesota got a Pediatric Device Innovation Consortium
  • 5 medtech stories we missed this week: April 20, 2018
  • FDA OKs Opus breast implant line from Sientra
  • Sollis lands $50m for long-acting pain-relief drug
  • Chinese investor group acquires Esaote
  • GE Healthcare’s sales, profits up in Q1
  • Qiagen wins FDA nod for point-of-care PartoSure test
  • Valeritas taps Glooko’s data management platform for next-gen insulin delivery device
  • Arthrosurface wins FDA nod for OVOMotion shoulder arthroplasty system

RSS From Medical Design & Outsourcing

  • How Minnesota got a Pediatric Device Innovation Consortium
    FDA funds a handful of pediatric device innovation groups around the United States. But Dr. Gwenyth Fischer, director of The Pediatric Device Innovation Consortium at the University of Minnesota, thinks there’s something that sets the seven-year-old group apart. The Minnesota group, Fischer said, is focused not only on funding but on getting doctors and other academics […]
  • Zeiss adds Xradia Context microCT to X-ray portfolio
    Zeiss has launched its new X-ray imaging instrument the Xradia Context microCT, which is a large field-of-view, non-destructive 3D X-ray microcomputed tomography system. The new Zeiss system is a tomographic imaging solution for 3D characterization and inspection needs for a variety of applications. The system allows users to easily adjust the system to enable imaging […]
  • Medtech stories we missed this week: April 20, 2018
    From CHF Solutions’ new Italian distribution deal to Masimo’s CE Mark approval, here are five medtech stories we missed this week but thought were still worth mentioning. 1. CHF Solutions signs Italian distribution deal CHF Solutions announced in an April 17 press release that it has signed a new distribution agreement with TRX Italy to distribute […]
  • FDA OKs Opus breast implant line from Sientra, with Lubrizol manufacturing
    The FDA this week granted a pre-market approval supplement to Sientra (NSDQ:SIEN) for its Opus line of silicone breast implants. The implants are made in Wisconsin by Lubrizol LifeSciences subsidiary Vesta, which inked a contract manufacturing deal with Sientra back in August 2016. Sales of Sientra’s silicone breast implants ground to a halt in the autumn of 2015, when […]
  • Icon and Intel forge partnership for pharmaceutical analytics platform for clinical trials
    Icon and Intel have struck an deal that allows Icon to offer the Intel Pharma Analytics Platform in clinical trials. The financial details of the deal were not disclosed. The Intel platform is an edge-to-cloud artificial intelligence platform that allows clinical data to be remotely monitored while it continuously captures data for study participants who […]
  • OCTANe announces partnership with Small Cap Nation
    Orange County, Calif.–based life sciences accelerator organization OCTANe recently announced a strategic partnership with Small Cap Nation (SCN), a New York City–based financial media content distribution platform. SCN delivers breaking, on-demand news and information related to the domestic and international small-cap sector. It recently opened a Silicon Valley office. “This partnership will open an important source of capital […]
  • Cadence snapped up by private equity firm Kohlberg & Co.
    Officials at high-precision components and finished devices maker Cadence are selling the Staunton, Va.–based company to private equity outfit Kohlberg & Co. Financial terms of the definitive agreement, announced yesterday, were not disclosed. Cadence makes components and devices for advanced surgical and specialty industrial applications. Cadence CEO Alan Connor will continue to lead the company, and […]
  • Turns out graphene can fight bacteria on implants
    Graphene flakes that are arranged like spikes can kill bacteria and stop infections during implant surgery procedures, according to new research from Chalmers University of Technology in Göteborg, Sweden. Bacteria moves around the body in fluids like blood looking for an area to stick to. Once they find a place, the bacteria starts to grow […]
  • How augmented reality and virtual reality devices are boosting medicine
    Augmented reality (AR) and virtual reality (VR) devices have immense disruptive potential, with the capacity to change how the healthcare industry delivers patient care and provider training. These technologies are helping to take medicine outside clinical spaces and will present a wide range of opportunities for innovators as professionals continue to adapt. Tim Jennings,  Custom […]
  • TT Electonics wraps up acquisition of Stadium Group
    TT Electronics (Woking, U.K.) said today that it has completed its purchase of Stadium Group, a Reading, U.K.–based supplier of connectivity products and services, power supplies, human-machine interface (HMI) and electronic assemblies. Financial terms of the deal were not disclosed. Stadium products are used in applications including medical equipment, smart home, industrial robotics and aircraft cabin controls […]
  • Excelitas Technologies touts OmniCure at InPrint Industrial Inkjet Conference
    Excelitas Technologies is touting its OmniCure OV LED curing solutions at this year’s InPrint Industrial Inkjet Conference at The Palmer House Hilton in Chicago, May 1-2. The company will showcase its new OmniCure AC8-HD (high dose) series of UV LED curing systems that offer higher optical power and enhanced performance in the same air-cooled mechanical […]

Leave a Reply Cancel reply

You must be logged in to post a comment.

Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us
Privacy
Add us on FacebookMassDevice Network
Follow us on Twitter@MassDevice
Connect with us on LinkedInLinkedIn
Connect with us on Google PlusGoogle+

Copyright © 2018 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy